Mr David Houlihan-Burne is a Consultant orthopaedic surgeon at The Hillingdon and Mount Vernon Hospitals NHS Trust, specialising in knee and sports injury surgery. He qualified at St Marys Hospital Medical School in 1995 before embarking on a career in surgery. His orthopaedic training took place in various London teaching hospitals. He then undertook a knee and sports injury fellowship in Bristol where he gained further experience in knee reconstructive surgery. His research interests include innovate working practices to improve patient satisfaction and reduce lengths of hospital stay as well as advances in ligament reconstruction and knee cartilage preservation surgery. Mr Houlihan-Burne leads the Rapid Recovery Programme at Hillingdon Hospital which has shown dramatic increases in patient satisfaction and reduction in inpatient length of stay.
Adobe Flash Player not installed or older than 9.0.115!
Adobe Flash Player not installed or older than 9.0.115!
Volunteers are another group of 'The Unseen People of Mount Vernon'. Not only are they unseen but, as the word volunteers indicates, they are also unpaid. They give up their own time to help others and raise money for the hospital Comfort Fund, which goes back into helping the patients. You will note from comments in the video, this is a very satisfying use of your spare time. Why not think of joining up.
'Your Hospital Needs YOU'
Adobe Flash Player not installed or older than 9.0.115!
The Nuclear Medicine department is hidden away at the end of the main building on the lower ground floor, with the Endiscope Unit on the first floor.
Nuclear medicine allows radioactive markers to be administered to the patients and then tracked as they pass around the body, thus identifying abnormalities in the patient.Planning radiotherapy requires very specialised skills, pin-pointing exactly where radiation will be administered and ensuring that the patient is in precisely the same position each time they are treated .
Nuclear Medicine uses the application of radioactive materials to aid the diagnosis and for treatment of patients. Different radioactive isotope/chemical combinations are used depending on the part of the body under investigation or being treated. These decay naturally, emitting gamma (g) and beta (b) radiation.
Depending on the examination required, tests can just involve a series of simple blood tests, a collection of urine samples or being scanned. But all examinations involve the administration of a radioactive material either as a small injection or in a capsule form.All the scans are performed on a dedicated Gamma camera, which detects the radioactivity within the body and creates a computer image of the area of interest. The scans produced are usually viewed in conjunction with images from other modalities, such as, MRI, CT, Ultrasound and X-rays. These other imaging techniques demonstrate anatomy (what the skeleton or organ looks like), whereas the nuclear medicine scans demonstrate the physiology or metabolic activity (i.e. how the organ is working).As well as diagnostic tests the department also uses different radioactive isotopes for different kinds of therapeutic effects, the therapies vary from treating a hyperactive thyroid to alleviating bone pain for bone metastases.The nuclear medicine department at Mount Vernon Hospital consists of a multidisciplinary specialised team that includes 3 senior radiographers, 1 technologist, 4 physicists and 2 administrative staff.
Adobe Flash Player not installed or older than 9.0.115!
Gordon Rustin qualified from the Middlesex Hospital, London in 1971. He was appointed Senior Lecturer in Medical Oncology at the Charing Cross Hospital in 1984, but moved full-time to Mount Vernon Hospital to become Director of Medical Oncology in 1995. He was awarded an Honorary Professorship by UCL in 2001 and visiting Professorship by University of Hertfordshire in 2006. He has published widely on management of gynaecological cancers and germ cell tumours’, the use of tumour markers, especially CA 125, and on phase I, II and III trials. His definitions using CA 125 to define response and progression of ovarian carcinoma are internationally known as the “Rustin criteriaâ€.
Since 1990 he has been able to translate laboratory work on vascular targeting into the clinic. As chief investigator of the phase I trials of DMXAA, CA4P and OXI4503 he has developed a unique experience of running trials of vascular disruptive agents (VDAs). He has led the world in introducing functional imaging into determining the activity of VDAs. Because of his large referral practice, he is also able to contribute patients to many other trials. For 5 years until 2008 he was chairman of the ovarian cancer sub group of the NCRI gynaecological clinical studies group.
Part One
Adobe Flash Player not installed or older than 9.0.115!
Part Two
Adobe Flash Player not installed or older than 9.0.115!
